|1.||Ohdo, Shigehiro: 3 articles (11/2009 - 03/2003)|
|2.||Higuchi, Shun: 3 articles (11/2009 - 03/2003)|
|3.||Iwase, Masanori: 3 articles (11/2009 - 03/2003)|
|4.||Sonoki, Kazuo: 3 articles (11/2009 - 03/2003)|
|5.||Iida, Mitsuo: 3 articles (11/2009 - 03/2003)|
|6.||Lichtenberger, Lenard M: 2 articles (03/2013 - 06/2010)|
|7.||Dial, Elizabeth J: 2 articles (03/2013 - 06/2010)|
|8.||Tran, Duy M: 2 articles (03/2013 - 06/2010)|
|9.||Sasaki, Nobuhiro: 2 articles (11/2009 - 02/2008)|
|10.||Tselepis, Alexandros D: 2 articles (10/2006 - 12/2002)|
01/05/1990 - "The studies also showed that ouabain (but not sphingosine and lyso-PC) increased the affinity constant (K0.5) for K+, whereas sphingosine and lyso-PC (but not ouabain) increased K0.5 for Na+. Sphingosine and lyso-PC inhibited 86Rb uptake by intact human leukemia HL-60 cells at potencies comparable to those for inhibitions of purified Na,K-ATPase and protein kinase C. "
03/01/2003 - "Our results suggest that lyso-PC contents in LDL play an important role in atherogenesis under diabetic condition, which could be prevented by increased availability of vascular NO."
09/07/1998 - "Enhanced expression of IFN-gamma in T lymphocytes by lyso-PC may play a crucial role in atherogenesis."
08/14/1998 - "These results suggest that lyso-PC, in combination with other stimuli, may regulate CD4+ T cell functions to propagate local inflammatory reactions and also imply a novel role played by a modified lipid in the selection of Th1/Th2 immune response as well as in the T cell mediated pathogenesis in atherosclerosis."
07/01/2002 - "The results suggest that lyso-PC acts synergistically with the vasoactive compounds H2O2, TX-A2, 5-HT, Ang-II, ET-1, or U-II in inducing VSMC proliferation, which may play an important role in the progression of atherosclerosis."
01/01/1998 - "Lysophosphatidylcholine (lyso-PC) has been implicated in atherogenesis and the inflammatory process. "
12/01/2014 - "In the exposure group, a significant 0.66- to 0.80-fold reduction in lyso-PC levels, which may have resulted from repeated inflammation, was observed. "
06/01/2010 - "An LPS-induced increase in sPLA2 activity in the gastric lumen and its product, lyso-PC, are capable of directly disrupting the gastric hydrophobic layer and may contribute to gastric barrier disruption and subsequent inflammation."
09/01/2001 - "Lysophosphatidylcholine (Lyso-PC) is generally considered to promote tissue inflammation. "
03/29/1985 - "Since lyso-PC is a metabolite of a representative membrane phospholipid, we propose that lyso-PC and other lysophospholipids are mediators for activation of macrophages regardless of the type of inflammation-causative agent."
08/14/1998 - "Lysophosphatidylcholine (lyso-PC) accumulates in tissues undergoing inflammation and atherosclerosis, where an infiltration of T cells is also seen. "
09/01/2001 - "Phospholipase A2 (PLA2) has been suggested in the pathogenesis of acute pancreatitis, in part through the PLA2-generated phospholipid by-products, most notably lysophosphatidylcholine (lyso-PC). "
01/01/2001 - "Phospholipase A2 (PLA2) has been suggested to play an important role in the pathogenesis of acute pancreatitis, in part through the PLA2-generated phospholipid by-products, most notably lysophosphatidylcholine (lyso-PC). "
|2.||Protein Kinase C
|3.||Ouabain (G Strophanthin)
|4.||Adenosine Triphosphatases (ATPase)
|8.||Phospholipases A2 (Phospholipase A2)
|9.||1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)